房颤体循环栓塞事件:NOAC对比华法林的个体患者数据荟萃分析
中位随访25.2个月期间,188例发生体循环栓塞,年化事件率为0.13%,显著低于缺血性卒中的1.25%。
要点
- NOAC较华法林显著降低房颤患者体循环栓塞风险29%。
- 外周动脉疾病、吸烟、非阵发性房颤等是体循环栓塞的独立预测因素。
核心结论
- 标准剂量NOAC较华法林显著降低房颤患者体循环栓塞风险29%(HR 0.71,95%CI 0.51-0.99,P=0.04)。
- 体循环栓塞后长期死亡风险较无事件患者增加近3倍(HR 2.85,95%CI 2.11-3.85)。
研究设计与样本
- 比较NOAC与华法林,中位随访25.2个月(四分位距17.5-32.0)。
主要发现
- 缺血性卒中年化事件率1.25%/患者年(n=1797)。
- 171例以体循环栓塞为首发事件的患者中位年龄75岁(四分位距68-80),49.7%为女性,CHA2DS2-VASc评分均值±标准差为4.7±1.5。
- 与缺血性卒中相比,体循环栓塞患者外周动脉疾病比例更高(16.5%对5.4%,P<0.001)。
- 与缺血性卒中相比,体循环栓塞患者既往心肌梗死比例更高(24%对17%,P=0.02)。
关键数值与推荐
- 体循环栓塞的独立预测因素包括:外周动脉疾病、吸烟、非阵发性房颤、女性、既往心肌梗死、既往卒中或短暂性脑缺血发作、维生素K拮抗剂使用经历及肾功能不全。
临床怎么用
- 房颤患者抗凝治疗选择时,NOAC在预防体循环栓塞方面优于华法林,可优先考虑。
- 合并外周动脉疾病、既往心肌梗死、非阵发性房颤或肾功能不全的房颤患者需警惕体循环栓塞风险。
局限性
- 体循环栓塞事件总数较少,仅188例,可能影响亚组分析的统计效能。
- 原始试验入组时间为2005至2010年,距当前临床实践已有较长时间间隔。
- 体循环栓塞的诊断标准在各原始试验之间可能不完全一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic embolic events (SEEs) are a serious but underrecognized complication of atrial fibrillation. Although non-vitamin K antagonist oral anticoagulants prevent ischemic stroke (IS), their efficacy in SEE and the clinical characteristics of patients who experience SEE remain poorly understood. METHODS: We analyzed individual patient data from 4 pivotal randomized trials enrolling patients between 2005 and 2010 comparing non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation. We characterized the incidence, clinical features, management, and outcomes of clinically overt SEE and compared results in these patients with patients who had an IS. RESULTS: Among 71 683 patients, 188 experienced SEE (26 with concurrent IS), yielding an annualized event rate of 0.13% per patient-year, compared with 1.25% per patient-year for IS (n=1797). Among 171 patients with SEE as their first event, median age was 75 years (interquartile range, 68-80), 49.7% were female, and mean±SD CHA2DS2-VASc score was 4.7±1.5. Compared with IS, patients with SEE had higher rates of peripheral arterial disease (PAD, 16.5% versus 5.4%; P<0.001), previous myocardial infarction (24% versus 17%; P=0.02), previous vitamin K antagonist exposure (57% versus 46%; P=0.007), worse renal function (median creatinine clearance 58 versus 62 mL/min; P=0.02), and higher incidence of nonparoxysmal atrial fibrillation (86% versus 80%; P=0.047). Interventions (surgical or percutaneous) were performed in 62 patients (31%) with SEE. Standard-dose non-vitamin K antagonist oral anticoagulants reduced the risk of SEE by 29% compared with warfarin over a median follow-up of 25.2 months (interquartile range, 17.5-32.0; hazard ratio, 0.71 [95% CI, 0.51-0.99]; P=0.04). Thirty-day mortality after SEE was similar to IS (18% versus 17%), and SEE was associated with a nearly 3-fold increased risk of long-term mortality compared with patients without SEE or IS (hazard ratio, 2.85 [95% CI, 2.11-3.85]). Independent predictors of SEE included peripheral artery disease, smoking, nonparoxysmal atrial fibrillation, female sex, previous myocardial infarction, previous stroke or transient ischemic attack, vitamin K antagonist experience, and renal dysfunction. CONCLUSIONS: In this large individual patient data meta-analysis, non-vitamin K antagonist oral anticoagulants significantly reduced the risk of SEE compared with warfarin. Although SEEs were approximately one-tenth as frequent as IS, they were associated with comparable mortality and substantial morbidity.
引用
- Al Said, Braunwald, Palazzolo, et al. Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus Warfarin. Circulation. 2026. PMID: 41614257. doi:10.1161/CIRCULATIONAHA.125.075275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。